

Current Grant Support:

NIH/NCI R01CA240360 (Multi-Principal Investigator) “Characterization of brain dysfunction during development in survivors of childhood acute lymphoblastic leukemia.” Annual direct support, \$752,031. Funding period: March 1, 2020 – February 28, 2025.

NIH/NCI R01 CA220568 (Multi-Principal Investigator) “Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL” Annual direct support \$563,152. Funding period 09/17/18-8/31/23.

Pending Grant Support

NIH/NCI R01CA248677 (Multi-Principal Investigator) “Poverty and Risk of Treatment-Associated Neurological Decline Due to Oxidative Stress During Childhood Leukemia Therapy” Annual direct support, \$625,000. Proposed funding period April 1, 2021 – March 30, 2026.

Completed Grant Support

NIH/NCI R01-CA182284 (Principal Investigator) “Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats.” Annual Direct Support \$207,500. Funding period: June 1, 2014-May 31, 2019.

Children’s Hospital of Philadelphia, Contracting on behalf ofThe Children’s Oncology Group, under Grant No. U10 CA098543: “AHOD1221 A Phase 1/2 Trial of Brentuximab Vedotin (SGN35, IND# 117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma.” Principal Investigator. \$15,000 Annual Direct Support. Funding Period: January 1, 2014 – December 31, 2018.

Rutgers Brain Health Institute Pilot Grants Program in Neuroscience (Multi-PI) “Cognitive control deficits in childhood leukemia survivors: At the intersection of brain, behavior, and computation”. Annual Direct Support, \$40,000. Funding Period, 1/24/19-1/23/20.

NIH/NCI R21-CA187226. (Principal Investigator) "Markers of Cognitive Decline During Treatment for Childhood ALL" Annual Direct Support \$125,000. Funding period 9/1/2015 - 8/31/2018.

St. Baldrick’s Foundation Consortium Research Grant (Co-Investigator) “Precision-Based Therapy for Childhood Leukemia” Funding Period: 07/01/2016 - 06/30/2021.

Children with Cancer UK. (CoInvestigator) “Biomarkers and discovery of new therapeutic targets for chemotherapy associated neurotoxicity.” Annual direct support £166,088. Funding Period: July 1, 2014 – March 31, 2016.

Einstein Nathan Shock Aging Center (CoInvestigator) “Assessment of accelerated aging in survivors of childhood cancer using microRNA-seq” Funding Period: August 1, 2014 – July 31, 2015

St Baldrick’s Foundation. (Principal Investigator) “Genetic predictors of chemotherapy-induced cognitive dysfunction.” Principal Investigator. Annual direct support, \$50,000. Funding period: 7/1/2012 – 6/30/2014.

St Baldrick’s Foundation. (Principal Investigator) “Pharmacologic prevention of chemotherapy-induced cognitive dysfunction.” Principal Investigator. Annual direct support, \$50,659. Funding period: 7/1/2010 – 6/30/2011.

American Institute of Cancer Research. (Co-Principal Investigator) “Does dietary folate intake modify treatment-related toxicity or disease outcome among children with acute lymphoblastic leukemia?” \$11,000 annual direct support [subcontract]. Funding period: 1/1/2010 – 12/31/2010.

Albert Einstein College of Medicine ICTR Collaborative investigator-initiated clinical and translational research grant. (Principal Investigator) “Defining Predictors of Chemotherapy-Induced Neurocognitive Dysfunction Among Patients With Childhood Leukemia.” \$30,000 annual direct support. Funding period 7/1/2009 – 6/30/2011.

Children's Evaluation And Rehabilitation Center Internal Grant-Making Program (Principal Investigator) “Does cancer chemotherapy acutely affect cognitive function?” \$20,000 annual direct support. Funding period 8/1/2008 – 7/31/2010.

Damon Runyon-Lilly Clinical Investigator Award (Principal Investigator) "Improving the therapeutic index for children with acute lymphoblastic leukemia through studies of folate physiology and antifolate pharmacodynamics." \$205,000 annual direct support. Funding period: 7/1/2003 - 12/31/2008.

National Childhood Cancer Foundation/The Children's Oncology Group, Subcontract No. 14134, under Grant No. U10 CA98543-03: "AHOD0321 A Phase II Study of Weekly Gemcitabine and Vinorelbine in Children with Recurrent or Refractory Hodgkin Disease" \$9,675 Annual Direct Support. Funding Period: March 1, 2003 - February 29, 2008.

Cancer Institute of New Jersey Pilot Project Research Award: "Animal modeling of antifolate-induced neurotoxicity." \$39,989 direct support. Period of funding: 1/1/07 - 12/31/07.

NIH K23 Mentored Patient-Oriented Research Career Development Award (1K23CA102346-01): "Improving antifolate therapy for patients with leukemia" Funding period: 7/1/2003 - 6/30/2008 (declined)

Clinical Scholars Biomedical Research Fellowship, 1998-1999: "Investigating the Roles of FPGS and GGH in MTX metabolism." Sloan-Kettering Institute. Annual support of \$30,000.

Publications:

A. Manuscripts (68 total; 14 senior author; 15 first author)

1. Egan-Sherry D, Bhuta R, **Cole PD**, Gennarini LM, Kahn JM, Sulis ML, DeNardo BD, Welch JJG. Severe vincristine-related neurotoxicity in five patients with pediatric acute lymphoblastic leukemia requiring discontinuation of vincristine: a description of long-term outcome. *J Pediatr Hematol Oncol*. 2021; *in press*.
2. Khullar K, Plascak JJ, Drachtman R, Cole, PD, Parikh RR. Associations between Race and Overall Survival in Pediatric Patients with Diffuse Large B Cell Lymphoma. *Cancer Medicine*. 2021; published online 1/27/21; <https://doi.org/10.1002/cam4.3736>.
3. Pikman Y, Tasian SK, Sulis ML, Stevenson KK, Blonquist T, Winger BA, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, **Cole PD**, Kahn JM, Chen J, Barth MJ, Magee J, Gennarini L, Adhav AA, Clinton CM, Ocasio-Martinez N, et. al. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-risk Leukemias: A Report from the LEAP Consortium. *Cancer Discovery*, 2021; *in press*.
4. Song Y, Zhu Q, **Cole PD**, Stevenson K, Harris M, Schultz E, Kahn JM, Ladas EJ, Athale UH, Clavell L, Laverdiere C, Leclerc J-M, Michon B, Welch JJG, Sallan SE, Silverman LB, Kelly K. Genetic Ancestry and Skeletal Toxicities among Childhood Acute Lymphoblastic Leukemia Patients in the DFCI 05-001 Cohort. *Blood Advances* 2020; 5(2):451-8.
5. Kahn J, Puligandla M, Stevenson K, **Cole P**, Welch J, Beauchemin M, Gage-Bouchard E, Silverman L, Kelly K, Bona K. Oral Mercaptopurine Adherence In Pediatric ALL: A Survey Study From The DFCI ALL Consortium. *J Pediatr Hematol Oncol*; under review.
6. Moerdler S, Ewart M, Friedman DL, Kelly K, Pei Q, Peng M, Zang XX, **Cole PD**. LAG-3 is Expressed on a Majority of Tumor Infiltrating Lymphocytes in Pediatric Hodgkin Lymphoma. *Leukemia & Lymphoma*. 2020; published online 28 Oct 2020. DOI: 10.1080/10428194.2020.1839651.
7. Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, **Cole PD**, Gennarini LM, Kahn JM, Kelly KM, Laverdierre C, Leclerc J-M, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Identification of Prognostic Factors in Childhood T-cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. *Pediatric Blood & Cancer*. 2021; 68:e28719. PMID: 33026184
8. Ladas EJ, Blonquist TM, Puligandla M, Orjuela M, Stevenson K, **Cole PD**, Athale UH, Clavell LA, Leclerc J-M, Laverdiere C, Michon B, Schorin MA, Welch JG, Asselin BL, Sallan SE, Silverman LB, Kelly KM. The protective effects of dietary intake of antioxidants and treatment-related toxicity in childhood leukemia: A Report from the DALLT Cohort. *Journal of Clinical Oncology*, 2020; 38(19): 2151-2159. PMID: 32330103
9. Savage B, Thomas-Hawkins C, **Cole PD**, Stapleton JL, de Cordova PB. Increased Risk of Severe Sepsis in Hispanic Children Hospitalized with Acute Myeloid Leukemia. *Journal of Pediatric Oncology Nursing*, 2020; *online publication date: 22 May 2020*. doi:10.1177/1043454220919699. PMID: 32441561

10. Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J, Gray J, Georger B, Minard-Colin V, Marshall LV, Smith M, Sondel P, Bajars M, Baldazzi C, Barry E, Blackman S, Blanc P, Capdeville R, Caron H, **Cole PD**, et al. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for Medicinal Product Development of checkpoint inhibitors for use in combination therapy in paediatric patients. *European Journal of Cancer*. 2020; 110:74-85. PMID: 31986450
11. Khullar K, Rivera-Nunez Z, Jhawar SR, Drachtman RA, **Cole PD**, Hoppe BS, Parikh RR. Pediatric Hodgkin Lymphoma: Disparities in Survival by Race. *Leukemia & Lymphoma*, 2020; 61(3): 546-556; *published Online 23 October 2019*. PMID: 31640446
12. Brace K, Lee W, **Cole PD**, Sussman E. (2019). Childhood leukemia survivors exhibit deficiencies in sensory and cognitive processes, as reflected by event-related brain potentials after completion of curative chemotherapy: A preliminary investigation. *Journal of Clinical and Experimental Neuropsychology*; 2019 Oct;41(8):814-831. DOI: 10.1080/13803395.2019.1623865. PMID: 31156064
13. Kelly KM, **Cole PD**, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz S. Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. *British Journal of Haematology*. 2019;187(1): 39-48. [HTTPS://doi.org/10.1111/bjh.16014](https://doi.org/10.1111/bjh.16014).
14. Ladas EJ, Orjuela M, Stevenson K, **Cole PD**, Lin M, Athale UH, Clavell LA, Leclerc JM, Laverdiere C, Michon B, Schorin MA. Fluctuations in Dietary Intake During Treatment for Childhood Leukemia: A Report from the DALLT Cohort. *Clinical Nutrition*. 2019;38(6):2866-2874
15. Jhawar SR, Rivera-Núñez Z, Drachtman R, **Cole PD**, Hoppe BS, Parikh RR. Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma. *JAMA Oncol*. Published online January 03, 2019. doi:10.1001/jamaoncol.2018.5911.
16. Wen J, Maxwell RR, Wolf AJ, Spira M, Gulinello ME, **Cole PD**. Methotrexate causes persistent deficits in memory and executive function in a juvenile animal model. *Neuropharmacology*. 2018; 139:76-84. <https://doi.org/10.1016/j.neuropharm.2018.07.007>. PMID: 29990472
17. **Cole PD**, McCarten KM, Pei Q, Spira M, Metzger ML, Drachtman RA, Horton TM, Bush R, Blaney SM, Weigel BJ, Kelly KM. Brentuximab vedotin with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma: A Children's Oncology Group, Single-arm, Phase 1 / 2 Trial. *The Lancet Oncology* 2018 Sep;19(9):1229-1238. doi: 10.1016/S1470-2045(18)30426-1. PMID: 30122620.
18. Vrooman LM, Blonquist TM, Harris MH, Stevenson KE, Place AE, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, **Cole PD**, Kelly KM, Laverdiere C, Leclerc J-M, Michon B, Schorin MA, Sulis ML, Welch JGG, Neuberg DS, Sallan SE, Silverman LB. Refining Risk Classification in Childhood B Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 05-001. *Blood Advances*, 2018; 2 (12), 1449-1458.
19. Athale UH, Puligandla M, Stevenson KE, Asselin B, Clavell LA, **Cole PD**, Kelly KM, Laverdiere C, Leclerc J-M, Michon B, Schorin MA, Sulis ML, Welch JGG, Harris MH, Neuberg DS, Sallan SE, Silverman LB. Outcome of children and adolescents with Down syndrome (DS) treated on Dana-Farber Cancer Institute (DFCI) acute lymphoblastic leukemia (ALL) Consortium Protocols 00-001 and 05-001. *Pediatric Blood and Cancer*, 2018;e27256. <https://doi.org/10.1002/pbc.27256>; published online June 7, 2018;
20. Tran TH, Harris MH, Nguyen JV, Blonquist TM, Stevenson KE, Stonerock E, Asselin BL, Athale UH, Clavell LA, **Cole PD**, Kelly KM, Laverdiere C, Leclerc J-M, Michon B, Schorin MA, Welch JGG, Reshmi S, Neuberg DS, Sallan SE, Loh ML, Silverman, LB. Prognostic Impact of Kinase-Activating Fusions and IKZF1 Gene Deletions in Pediatric High-Risk B-Lineage ALL. *Blood Advances*, 2018; 2 (5): 529-33.
21. Sulis ML, Blonquist TM, Athale UH, Clavell LA, **Cole PD**, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JG, Neuberg DS, Sallan SE and Silverman LB. Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. *Pediatric Blood and Cancer*, 2018; 65(5): e26952. published online 10 Jan. 2018; DOI: 10.1002/pbc.26952.
22. Kahn JM, **Cole PD**, Blonquist TM, Stevenson K, Jin Z, Barrera S, Davila R, Roberts E, Neuberg DS, Athale UH, Clavel LA, Laverdiere C, Leclerc J-M, Michon B, Schorin MA, Welch JGG, Sallan SE, Silverman LB, Kelly KM. An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001. *Pediatric Blood and Cancer*, 2017; Published online Nov 1. PMID: 29090520.

23. Thomsen AM, Gulinello ME, Vijayanathan V, Wen J, Schmiegelow K, **Cole PD**. Liposomal Cytarabine Induces Less Neurocognitive Dysfunction than Intrathecal Methotrexate in an Animal Model. *Journal of Pediatric Hematology / Oncology*. 2018; 40 (2), e91-e96; published online July 17 2017. PMID: 28654460.
24. Maxwell RR, **Cole PD**. Pharmacogenetic Predictors of Treatment-Related Toxicity among Children with Acute Lymphoblastic Leukemia. *Current Hematologic Malignancy Reports*. 2017; 23(3): 176-86 PMID: 28317081
25. Finkelstein Y, Blonquist TM, Vijayanathan V, Stevenson KE, Neuberger DS, Silverman LB, Vrooman LM, Sallan SE, **Cole PD**. A Thymidylate Synthase Polymorphism is Associated with Increased Risk for Bone Toxicity Among Children Treated for Acute Lymphoblastic Leukemia. *Pediatric Blood & Cancer*. 2017; 64(7): e26393; Published online 13 Dec. 2016. PMID: 27957785
26. Sands SA, Harel BT, Savone M, Kelly K, Vijayanathan V, Welch JG, Vrooman L, Silverman LB, **Cole PD**. Feasibility of Baseline Neurocognitive Assessment using Cogstate During the First Month of Therapy for Childhood Leukemia. *Supportive Care in Cancer*. 2016; published online October 12. PMID: 27726029
27. Kahn J, Athale, UH, Clavell LA, **Cole PD**, Leclerc J-M, Laverdiere C, Michon B, Schorin MA, Welch JG, Sallan SE, Silverman LB, Kelly KM. How variable is our delivery of information? A survey of medical providers assessing provider-driven patient teaching about oral chemotherapy regimens for pediatric patients with acute lymphoblastic leukemia. *Journal of Pediatric Health Care*. 2016, *published online July 25*. PMID: 27461368
28. Ladas EJ, Orjuela M, Stevenson K, **Cole PD**, Lin M, Athale UH, Clavell LA, Leclerc J-M, Michon B, Schorin MA, Welch JG, Asselin B, Sallan S, Silverman LB, Kelly KM. The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) Cohort Study: Rationale, Design, and Baseline Characteristics. *Nutrition*. 2016; *published online March 28*. PMID: 27318855
29. Figueiredo L, **Cole PD**, Drachtman RA. Asparaginase *Erwinia chrysanthemi* as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to *E. coli*-derived asparaginase. *Expert Rev Hematol*. 2016 Mar;9(3):227-34.
30. Drachtman RA, Masterson M, Shenkerman A, Vijayanathan V, **Cole PD**. Long-term outcomes for children with acute lymphoblastic leukemia (ALL) treated on the Cancer Institute of New Jersey ALL trial (CINJALL). *Leukemia and Lymphoma* 2016; 57(10):2275-80. PMID: 26879921
31. Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, Supko J, Asselin B, Athale UH, Clavell LA, **Cole PD**, Kelly KM, Laverdiere C, Leclerc J-M, Michon B, Schorin MA, Welch J, Lipshultz SE, Blonquist T, Neuberger DS, Sallan E, Silverman LB. Phase III Randomized Comparison of Intravenous Pegasparginase and Intramuscular Native *E. coli* L-Asparaginase in Newly Diagnosed Childhood ALL: Results of DFCI Protocol 05-001. *Lancet Oncology*; 2015; 16(16): 1677-90. PMID: 26549586.
32. **Cole PD**, Finkelstein Y, Stevenson KE, Blonquist TM, Vijayanathan V, Silverman LB, et al. Polymorphisms in Genes Related to Oxidative Stress Are Associated with Inferior Cognitive Function after Therapy for Childhood Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*. 2015; 33(19):2205-11. PMID: 25987702
33. Horton TM, Drachtman R, Chen L, **Cole PD**, McCarten K, Voss SD, et al. A Phase 2 Study of Bortezomib in Combination with Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults with Refractory/Recurrent Hodgkin Lymphoma: A Children's Oncology Group (COG) Study. *British Journal of Haematology*. 2015 Jul;170(1):118-22. PMID: 25833390
34. Perales M-A, Ceberio P, Burns L, Chen R, **Cole PD**, Evens AM, et al. The Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: An Evidence-Based Review by the American Society for Blood and Marrow Transplantation Committee on Practice Guideline. *Biology of Blood and Marrow Transplantation*. 2015; 21(6):971-983. doi: 10.1016/j.bbmt.2015.02.022.
35. Kim S-E, Hinoue T, Kim MS, Sohn K-J, Cho RC, **Cole PD**, Weisberger DJ, Laird PW, Kim YI. g-Glutamyl hydrolase modulation significantly influences global and gene-specific DNA methylation and gene expression in human colon and breast cancer cells. *Genes and Nutrition*, 2015; 10(1): 444. PMID: 25502219
36. Harker-Murray P, Drachtman RA, Hodgson DC, Chauvenet AR, Kelly KM, **Cole PD**. Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. *Pediatric Blood & Cancer*, 2014; 61(4): 579-586. PMID: 24504790

37. Kim S-E, **Cole PD**, Cho R, Ly A, Ishiguro L, Sohn K-J, Croxford R, Kamen B, Kim Y-I. γ -Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate. *British Journal of Cancer* 2013; 109: 2175-88. PMID: 24045662
38. **Cole PD**, Vijayanathan V, Ali NF, Wagshul ME, Tanenbaum EJ, Price J, Dalal V, Gulinello ME. "Memantine protects rats treated with intrathecal methotrexate from developing spatial memory deficits," *Clinical Cancer Research* 2013; 19(16):4446-54. PMID: 23833301.
39. Becton LJ, Goilav B, Wang Y, **Cole PD**, Kaskel F. 18 year old with nephrotic syndrome and chest pain. *Pediatric Nephrology*. 2015; 30(2): 267-71. Published online Nov. 22, 2013. DOI: 10.1007/s00467-013-2646-x. PMID: 24263532.
40. Kelly KM, Hodgson D, Appel B, Chen L, **Cole PD**, Horton T, Keller FG, on behalf of the, 'Children's Oncology Group's 2013 Blueprint for Research: Hodgkin Lymphoma', *Pediatric Blood & Cancer* (2012), 60(6):972-8. PMID: 23255501.
41. Vijayanathan V, Ali N, Gulinello M, **Cole PD**. Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist. *Behavioural Brain Research*. 2011;225(2):491-7.
42. Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, **Cole PD**, Kelly KM, Larsen EC, Laverdiere C, Michon B, Schorin M, Schwartz CL, Cohen HJ, Lipshultz SE, Silverman LB, and Sallan SE. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. *European Journal of Cancer* 2011;47: 1373-1379.
43. Mahadeo KM, Wolgast L, McMahon C, **Cole PD**. Systemic Mastocytosis in a Child With t(8;21) Acute Myeloid Leukemia. *Pediatric Blood & Cancer*, 2011; 27(8):650-7.
44. **Cole PD**, McCarten KM, Drachtman RA, de Alarcon P, Chen L, Trippett TM, Schwartz CL. Early FDG-PET-based Response Evaluation After Treatment with Gemcitabine and Vinorelbine for Refractory Hodgkin Disease: A Children's Oncology Group Report. *Pediatric Hematology and Oncology*; 2010; 27(8): 650-7.
45. Mahadeo KM, **Cole PD**. Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 35INS. *Blood* 2010; 115(18): 3852.
46. Li Y, Vijayanathan V, Gulinello M, **Cole PD**. Intrathecal Methotrexate Induces Focal Cognitive Deficits and Increases Cerebrospinal Fluid Homocysteine. *Pharmacology, Biochemistry and Behavior*;2010; 95 (4): 428-33.
47. Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, **Cole PD**, Kelly K, Laverdiere C, Michon B, Schorin M, Schwartz CL, O'Brien JE, Cohen HJ, Sallan SE. Intravenous PEG-Asparaginase During Remission Induction in Children and Adolescents with Newly Diagnosed Acute Lymphoblastic Leukemia. *Blood* 2010; 115(7):1351-3.
48. Li Y, Vijayanathan V, Gulinello ME, **Cole PD**. Systemic Methotrexate Induces Spatial Memory Deficits and Depletes Cerebrospinal Fluid Folate in Rats. *Pharmacology, Biochemistry and Behavior* 2010; 94(3):454-63.
49. Silverman LB, Stevenson K, O'Brien JE, Asselin BL, Athale UH, Clavell L, **Cole PD**, Kelly K, Laverdiere C, Michon B, Schorin M, Schwartz CL, O'Holleran EW, Neuberg DS, Cohen HJ, Sallan SE. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). *Leukemia* 2010; 24(2): 320-34.
50. **Cole PD**, Beckwith KA, Vijayanathan V, Roychowdhury S, Smith AK, Kamen BA. CSF Folate Homeostasis During Therapy for Acute Lymphoblastic Leukemia. *Pediatric Neurology* 2009; 40(1): 34-41.
51. **Cole PD**, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett T. Phase 2 Study of Weekly Gemcitabine and Vinorelbine for Children with Recurrent or Refractory Hodgkin Disease, A Children's Oncology Group Report. *Journal of Clinical Oncology*. 2009; 27(9): 1456-61.
52. Wollack JB, Makori B, Ahlawat S, Koneru R, Picinich S, Smith AK, Goldman ID, Qiu A, **Cole PD**, Glod J, Kamen BA. Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. *Journal of Neurochemistry*, 2008; 104(6): 1494-503.

53. Cho RC, **Cole PD**, Sohn KJ, Gaisano G, Croxford R, Kamen BA, Kim YI. Effects of folate and folypolyglutamyl synthase modulation on chemosensitivity of breast cancer cells. *Molecular Cancer Therapeutics*, 2007; 6(11): 2909-20.
54. Vijayanathan V, Smith AK, Zebala JA, Kamen BA, **Cole PD**. HPLC Separation of Aminopterin Polyglutamates Within Red Blood Cells of Children Treated for Acute Lymphoblastic Leukemia. *Translational Research*, 2007; 150(6) 367-73.
55. **Cole PD**, Drachtman RA, Masterson M, Smith AK, Glod J, Zebala JA, Lisi S, Drapala D-A, Kamen BA. Phase IIB Trial Of Aminopterin In Multiagent Therapy For Children With Newly Diagnosed Acute Lymphoblastic Leukemia at High Risk of Relapse. *Cancer Chemotherapy and Pharmacology*, 2008; 62:65-75.
56. **Cole PD**, Kamen BA. Delayed Neurotoxicity Associated with Therapy for Patients with Childhood Leukemia. *Mental Retardation and Developmental Disabilities Research Reviews*. 22006; 12(3): 174-83.
57. **Cole PD**, Drachtman RA, Smith AK, Cate S, Larson RA, Hawkins DS, Holcenberg J, Kelly K, Kamen BA. Phase II Trial of Oral Aminopterin for Adults and Children with Refractory Acute Leukemia. *Clinical Cancer Research* 2005; 11(22): 8089-96.
58. **Cole PD**, Alcaraz MJ, Smith AK, Tan J, Kamen BA. Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy. *Cancer Chemotherapy and Pharmacology*. 2006; 57(6):826-34. Epub 2005 Sep 17.
59. Hochhauser CJ, Lewis M, Kamen BA, **Cole PD**. Steroid Induced Alterations of Mood and Behavior in Children During Treatment for Acute Lymphoblastic Leukemia. *Supportive Care in Cancer*. 2005; 13(12): 967-74.
60. Li WW, Su D, Mizobuchi H, Martin DS, Gu B, Gorlick R, **Cole P**, and Bertino JR. Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. *Oncology Research*, 2004; 14: 373-379.
61. Kaufman Y, Drori S, **Cole PD**, Kamen BA, Sirota J, Ifergan I, Ben Arush MW, Elhasid R, Sahar D, Kaspers GJL, Jansen G, Matherly LH, Rechavi G, Toren A, Assaraf YG. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia. *Cancer*. 2004; 100(4): 773-82.
62. **Cole PD**, Smith AK, Kamen BA. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs. *Cancer Chemotherapy and Pharmacology* 2002; 50(2): 111-6.
63. Drachtman RA, **Cole PD**, Golden CB, James SJ, Melnyk S, Aisner J, Kamen BA. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. *Pediatric Hematology and Oncology*, 2002; 19(5): 319-327.
64. **Cole PD**, Gorlick R, Banerjee D, Magill L, Smith A, Kamen BA, Bertino JR. Effects Of Overexpression Of γ -Glutamyl Hydrolase (GGH) On Methotrexate Metabolism And Resistance. *Cancer Research*, 2001; 61(11): 4599-4604.
65. **Cole PD**, Suh JS, Onel K, Stiles J, Armstrong D, Dunkel IJ. Benign Outcome Of RSV Infection In Children with Cancer. *Medical and Pediatric Oncology*, 2001; 37(1): 24-9.
66. **Cole PD**, Stiles J, Boulad F, Small TN, O'Reilly RJ, George D, Szabolcs P, Kiehn TE, Kernan NA. Successful treatment of Human Herpes Virus-6 encephalitis in a bone marrow transplantation recipient. *Clinical Infectious Diseases*, 1998; 27:653-4.
67. **Cole P**, Ladanyi M, Gerald WL, Cheung N-K V, Kramer K, LaQuaglia MP, Kushner BH. Synovial sarcoma mimicking desmoplastic small round-cell tumor: critical role for molecular diagnosis. *Medical and Pediatric Oncology*, 1999; 32: 97-101.
68. Gorlick R, **Cole P**, Banerjee D, Longo G, Li WW, Hochhauser D, Bertino JR. Mechanisms of methotrexate resistance in acute leukemia: Decreased transport and polyglutamylation. *Advances in Experimental Medicine & Biology*, 1999;457:543-50.

B. Abstracts

1. Gotti G, Puligandla M, Stevenson K, Mar B, **Cole P**, Gennarini L, Kahn J, Kelly K, Michon B, Tran T, Welch JG, Stegmaier K, Harris MH, Silverman LB, Pikman Y. Frequency and prognostic significance of recurrent gene mutations in pediatric B-ALL: report from the DFCI ALL Consortium. [oral presentation] American Society of Hematology Annual Meeting. December 2020.

2. Vrooman LM, Flamand Y, Koch VB, Burns M, Cronholm SM, Hunt SK, **Cole PD**, Gennarini LM, Kahn JM, Kelly KM, Michon B, Neuberg DS, Place A, Tran TH, Welch JG, Stevenson KE, Sallan SE, Silverman LB. Pegaspargase Re-challenge After Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001. [oral presentation] American Society of Hematology Annual Meeting. December 2020.
3. **Cole PD**, Mauz-Korholz C, Mascarin M, Michel G, Cooper S, Beischuizen A, Leger KJ, Amoroso L, Buffardi S, Rigaud C, Puhlman M, Francis S, Sacchi M, Drachtman RA, Harker-Murray P, Leblanc T, Daw S, Kelly K. Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis of the Standard Risk Cohort of the Phase 2 Checkmate 744 Study. [online poster presentation] Society of Hematologic Oncology Annual Meeting, Houston, TX. September 10, 2020.
4. Moerdler S, Ewart M, Peng M, Zang XX, **Cole PD**. LAG-3 overexpression in pediatric Hodgkin lymphoma. [online poster presentation] American Society of Clinical Oncology Annual Meeting, May 30, 2020.
5. **Cole PD**, Mauz-Korholz C, Mascarin M, Michel G, Cooper S, Beischuizen A, Leger KJ, Garaventa A, Buffardi S, Brugieres L, Harker-Murray P, Drachtman RA, Manley T, Francis S, Saachi M, Leblanc T, Daw S, Kelly K. Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis. [online poster presentation] American Society of Clinical Oncology Annual Meeting, May 30, 2020.
6. Harker-Murray P, Pei Q, Forlenza C, Drachtman R, **Cole PD**, Kelly KM. A New Model for Stratification of Treatment Intensity in Relapsed Pediatric Hodgkin Lymphoma. International Symposium on Childhood, Adolescent, and Young Adult Hodgkin Lymphoma. *Klinische Pädiatrie* 2020; 232: 101.
7. Savage B, **Cole PD**, Thomas-Hawkins C, Lin H. The Association Between Poverty and Pancreatitis in Children with Acute Lymphoblastic Leukemia is Dependent Upon Age. Eastern Nursing Research Society Annual Meeting. Boston, MA. March, 2020.
8. Zhu Q, Yao S, **Cole PD**, Kahn JM, Harris MH, Schiller E, Athale U, Clavell LA, Laverdiere C, Leclerc JM, Michon B. Genetic Ancestry and Skeletal Toxicities Among Childhood Acute Lymphoblastic Leukemia Patients in the DFCI 05-001 Cohort. American Society of Hematology Annual Meeting, Orlando, FL, December, 2019.
9. Savage B, Cole PD, Thomas-Hawkins C, Stapleton J, de Cordova P, Flynn L. Hispanic Race Is Associated with Increased Risk of Severe Sepsis in 1913 Hospitalizations of Children with AML and Infection. American Society of Hematology Annual Meeting, Orlando, FL, December, 2019. *Blood* (2019) 134 (Supplement_1): 1327.
10. Kelly KM, Daw S, Mauz-Korholz C, Mascarin M, Michel G, Cooper S, Beischuizen A, Leger KJ, Garaventa A, Buffardi S, Brugieres L, Harker-Murray P, **Cole PD**, Drachtman RA, Manley T, Francis S, Saachi M, Leblanc T. "Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin (BV) in Children, Adolescents, and Young Adults (CAYA) With Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): CheckMate 744 Subgroup Analyses." [poster presentation] Annual Meeting of the Society of Hematologic Oncology; Houston, TX. 11 Sept. 2019.
11. Mauz-Korholz C, Leblanc T, Harker-Murray P, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger KJ, Garaventa A, Buffardi S, Bruigieres L, Kelly KM, **Cole PD**, Drachtman RA, Manley T, Francis S, Saachi M, Daw S. "Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in primary refractory patients (pts) and in pediatric pts with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) in the phase 2 CheckMate 744 study" [Oral presentation] Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, Berlin, Germany. 13 October, 2019
12. Khullar K, Rivera-Nunez Z, Jhawar S, Drachtman R, **Cole PD**, Hoppe B, Parikh R. Survival Disparities by Race in Pediatric Hodgkin Lymphoma. [oral presentation] European Hematology Association Annual Meeting. Amsterdam, The Netherlands. June 13, 2019.
13. Leblanc T, Harker-Murray P, Mauz-Korholz C, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger KJ, Garaventa A, Buffardi S, Brugieres L, Kelly KM, **Cole PD**, Drachtman RA, Manley T, Francis S, Sacchi M, Daw S. Nivolumab And Brentuximab Vedotin-Based, Response-Adapted Treatment In Primary Refractory And In Pediatric Patients With Relapsed/Refractory Classical Hodgkin Lymphoma In Checkmate 744. European Hematology Association Annual Meeting. Oral Presentation. Amsterdam, The Netherlands. June 13, 2019.
14. Vrooman LM, Blonquist TM, Supko JG, Hunt SK, O'Brien JE, Kay-Green S, Athale UH, Clavell LA, Cole PD, Harris MH, Kelly KM. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute

- lymphoblastic leukemia/lymphoma: Results of DFCI 11-001. Annual Meeting of the American Society of Clinical Oncology, June 20, 2019; Journal of Clinical Oncology, 2019; 37(15 Suppl):10006.
15. Kelly KM, Daw S, Mauz-Korholz C, Mascarini M, Michel G, Cooper S, Beishuizen A, Leger KJ, Garaventa A, Buffardi S, Brugieres L, Harker-Murray P, **Cole PD**, Drachtman RA, Manley T, Francis S, Sacchi M, Leblanc T. Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: CheckMate 744 Subgroup Analyses. International Conference on Malignant Lymphoma. Oral Presentation. Lugano, Switzerland. June 19, 2019.
 16. Khullar K, Rivera-Nunez Z, Jhawar S, Drachtman R, **Cole PD**, Hoppe B, Parikh R. Survival Disparities by Race in Pediatric Hodgkin Lymphoma. American Society for Radiation Oncology Annual Meeting, Chicago IL, September 18, 2019.
 17. Brace K, Lee WW, **Cole PD**, Sussman ES. Childhood leukemia survivors exhibit chronic deficiencies in sensory and cognitive processes, as reflected by event-related brain potentials: A preliminary investigation. Cognitive Neuroscience Society, San Francisco, CA, March 23-26, 2019.
 18. Harker-Murray P, Leblanc T, Mascarini M, Mauz-Korholz C, Michel G, Cooper S, Beishuizen A, Leger K, Garaventa A, Buffardi S, Brugieres L, Kelly K, **Cole PD**, Drachtman RA, Galderisi F, Sacchi M, Daw S. Nivolumab, Brentuximab Vedotin, and Bendamustine as Response-Adapted Treatment for Relapsed or Refractory Hodgkin Lymphoma in Children, Adolescents and Young Adults: Results from the Standard-Risk Cohort of the Phase 2 CheckMate 744 Study. British Society for Haematology Annual Meeting, Glasgow, Scotland, April 2, 2019.
 19. Buhtoiarov I, Mba N, De Los Santos C, McCarten KM, Metzger ML, Pei Q, Bush R, Kelly KM, Flagg A, Hanna R, **Cole PD**. Durable remission for two patients with early relapse of hodgkin lymphoma, treated with brentuximab vedotin plus gemcitabine, without autologous stem cell transplantation: a report from the children's oncology group. 11th International Symposium on Hodgkin Lymphoma. Cologne, Germany. October 29, 2018.
 20. Harker-Murray P, Leblanc T, Mascarini M, Mauz-Korholz C, Michel G, Cooper S, Beishuizen A, Leger K, garaventa A, Buffardi S, Brugieres L, Kelly K, Cole PD, Drachtman RA, Galderisi F, Sacchi M, Jou Y-M, Daw S. Response-Adapted Therapy With Nivolumab and Brentuximab Vedotin (BV), Followed by BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults With Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma. American Society of Hematology Annual Meeting, San Diego CA, December 3, 2018.
 21. Pikman Y, Tasian SK, Sulis ML, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown P, Gossai N, Cole PD, McNeer J, Shukla N, Winger B, Adhav AA, Blonquist TM, Conway AS, Place AE, Gore L, Hunger SP, Janeway KA, Silverman LB, Tyner J, Harris M, Loh ML, Stegmaier K. Matched targeted therapy for pediatric patients with relapsed, refractory or high-risk leukemias: A report from the LEAP consortium. American Society of Hematology Annual Meeting, San Diego, CA. December 2, 2018.
 22. Pikman Y, Tasian SK, Sulis ML, Blonquist TM, Maloney KW, McNeer JL, Pauly MG, Shukla NN, Tyner J, Cole PD, Burke MJ, Gossai N, Brown PA, Gore L, Hunger S, Cooper TM, Silverman LB, Harris MH, Loh ML, Stegmaier K, Consortium PL (2018) Matched targeted therapy for pediatric patients with relapsed, refractory or high-risk leukemias: A report from the LEAP consortium. American Society of Clinical Oncology Annual Meeting, Chicago, IL. June 2018.
 23. Pikman Y, Tasian SK, Place AE, Asmani AA, Conway AS, Stieglitz E, Sulis ML, Blonquist TM, Maloney KW, McNeer J, Pauly M, Shukla N, Tyner J, **Cole PD**, Burke MJ, Gossai N, Brown P, Gore L, Hunger SP, Cooper TM, Janeway KA, Silverman LB, Harris M, Loh ML, Stegmaier K. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-risk Leukemias: A Report from the LEAP Consortium. Pediatric Precision Oncology Conference, Scottsdale, AZ. March 4, 2018.
 24. Cole PD, Spira M, McCarten KM, Horton TM, Pei Q, Metzger M, Drachtman RA, Kelly KM. Changes in Serum TARC Predict PET Response Among Pediatric Patients with Relapsed or Refractory Hodgkin Lymphoma Treated with Brentuximab Vedotin and Gemcitabine: A Report from the Children's Oncology Group. American Society of Hematology Annual Meeting, Atlanta GA, December 10, 2017
 25. Kelly KM, Ladas E, Blonquist TM, Stevenson KE, Lin M, **Cole PD**, Orjuela M, Athale U, Clavell LA, Laverdiere C, Leclerc J-M, Michon B, Schorin MA, Sulis ML, Welch JJG, Asselin BL, Sallan SE, Silverman LB. Dietary Antioxidant Micronutrient Intake and Toxicity during Remission Induction in Children with Acute Lymphoblastic

- Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001. American Society of Hematology Annual Meeting, Atlanta GA, December 10, 2017.
26. Athale UH, Blonquist TM, Stevenson KE, Spira M, **Cole PD**, Asselin BL, Clavell LA, Kelly KM, Laverdière C, Leclerc J-M, Michon B, Schorin MA, Sulis ML, Welch JGG, Harris MH, Neuberg DS, Sallan SE, Silverman LB. Age and ABO Blood Group Are Significant Predictors of Thrombosis in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001. American Society of Hematology Annual Meeting, Atlanta GA, December 9, 2017.
 27. **Cole PD**, McCarten K, Metzger M, Drachtman RA, Horton TM, Pei Q, Bush R, Blaney S, Weigel B, Kelly KM. Phase 2 trial of brentuximab vedotin and gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma (HL): A Children's Oncology Group (COG) report. American Society of Clinical Oncology Annual Meeting. June 5, 2017. Chicago IL.
 28. Lee I, Im H-J, McCarten K, Schwartz C, **Cole P**, Kelly K, Cho S. Evaluation of inter-observer reliability and assessment of PET SUV-based quantification of 5-point Deauville score in FDG PET/CT in a COG pediatric high risk Hodgkin lymphoma trial (AHOD0831). *Journal of Nuclear Medicine*. 2017; 58 (s1): 639.
 29. Finkelstein Y, Blonquist TM, Vijayanathan V, Stevenson KE, Neuberg DS, Silverman LB, Vrooman LM, Sallan SE, **Cole PD**. "Pharmacogenetic Determinants of Bone Toxicity Among Children Treated with Chemotherapy for Acute Leukemia" American College of Medical Toxicology, Annual Meeting. April 2 2017. San Juan, Puerto Rico.
 30. Athale UH, Puligandla M, Stevenson KE, Asselin BL, Clavell LA, **Cole PD**, Kelly KM, Laverdiere C, Leclerc J-M, Michon B, Schorin MA, Sulis ML, Welch JGG, Harris M, Neuberg DS, Sallan SE, Silverman LB. Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001. American Society of Hematology Annual Meeting, San Diego, CA 2016
 31. Silverman LB, Blonquist TM, Hunt SK, Kay-Green S, Athale UH, Clavell LA, **Cole PD**, Kelly KM, Laverdiere C, Leclerc J-M, Michon B, Schorin MS, Sulis ML, Welch JGG, Supko JG, He X, Hilderbrand S, Place AE, Vrooman LM, Harris MH, Stevenson KE, Neuberg DS, Sallan SE, Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001. American Society of Hematology Annual Meeting, San Diego CA 2016.
 32. Tran TH, Harris MH, Nguyen JV, Blonquist TM, Stevenson KE, Stonerock E, Asselin BL, Athale UH, Clavell LA, **Cole PD**, Kelly KM, Laverdiere C, Leclerc J-M, Michon B, Schorin MA, Welch JGG, Reshmi S, Neuberg DS, Sallan SE, Loh ML, Silverman, LB. Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia: a Report from the DFCI ALL Consortium. American Society of Hematology Annual Meeting, San Diego, CA 2016.
 33. Sands SA, Harel B, Silverman LB, **Cole PD**. Feasibility of Neurocognitive Baseline Assessment using Cogstate During the First Month of Therapy for Childhood Leukemia. International Cancer and Cognition Task Force Annual Meeting. Amsterdam, Netherlands, 2016.
 34. **Cole PD**, Blonquist TM, Vijayanathan V, Neuberg DS, Vrooman LM, Sallan SE, Silverman LB, Finkelstein Y. Homozygosity for the 2R Tandem Repeat Polymorphism in the Thymidylate Synthase (TS) Promoter Is Associated with Increased Risk for Bony Morbidity Among Children Treated for Acute Lymphoblastic Leukemia on DFCI Protocol 05-001. *Blood*. 2015 Dec 3;126(23):251.
 35. Sulis ML, Blonquist TM, Athale UH, Clavell LA, **Cole PD**, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ. Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. *Blood*. 2015 Dec 3;126(23):249.
 36. Harris MH, Blonquist TM, Athale UH, Clavell LA, **Cole PD**, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ. Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease. *Blood*. 2015 Dec 3;126(23):2613.
 37. Kahn J, Barrera S, Davila R, Roberts E, Jin Z, Stevenson K, Blonquist TM, Neuberg DS, Athale UH, Clavell LA, **Cole P**, Laverdiere C, Michon B, Schorin MA, Welch JJ, Sallan SE, Silverman LB, Kelly KM. Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001. *Blood*. 2015 Dec 3;126(23):248.

38. Kelly KM, **Cole PD**, Chen L, Roberts KB, Hodgson DC, McCarten K, Cho SY, Schwartz C. Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB)(AHOD0831): A Report from the Children's Oncology Group. *Blood*. 2015 Dec 3;126(23):3927.
39. **Cole PD**, Metzger M, Drachtman RA, Horton TM, Liu X, Ahern CH, Minard C, Fox E, Blaney S, Weigel B, Kelly KM. Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children's Oncology Group report. *InASCO Annual Meeting Proceedings 2015 May 20 (Vol. 33, No. 15_suppl, p. 8544)*.
40. **Cole PD**, Neuberg DS, Silverman LB, Stevenson KE, Vijayanathan V, Finkelstein Y, Sallan SE, Waber DP. Polymorphisms in Genes Related to Oxidative Stress Are Associated with Inferior Cognitive Function after Therapy for Childhood ALL. *American Society of Hematology Annual Meeting. Blood 2014; 124(21):856*.
41. Kelly KM, Ladas EJ, **P Cole**, LB Silverman, KE Stevenson, M Orjuela. Dietary Intake of Zinc and Severity of Infection during Prophase/Induction in Children with Acute Lymphoblastic Leukemia. *American Society of Hematology Annual Meeting. Blood 2014; 124(21):3659*.
42. Silverman LB, Stevenson, KE, Athale UH, Clavell LA, **Cole PD**, Kelly KA, Leclerc JM, Michon B, Schorin MA, Schwartz CL, et al., Results of the DFCI ALL Consortium Protocol 05-001 for Children and Adolescents with Newly Diagnosed ALL. *American Society of Hematology Annual Meeting, New Orleans, LA. December, 2013*.
43. El Hag M, Cohen M, Bardenstein D, Peereboom D, **Cole P**, Sloan A, Rogers L. Biopsy-proven multifocal necrotizing leukoencephalopathy following systemic methotrexate monotherapy for CNS metastasis of Non-Hodgkin Lymphoma. *American Academy of Neurology Annual Meeting, San Diego, CA. March, 2013*.
44. Vijayanathan V, Ali N, Gulinello M, Cole PD. The utility of glutamate antagonists for the prevention or reversal of chemotherapy-induced cognitive dysfunction. *International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer. Williamsburg, VA. June, 2012*.
45. Esteban-Cruciani N, **Cole PD**, Skae C, Vincencio A, Rajpathak S, Bauman L. "Implementation of a Departmental ACGME Compliant Core Curriculum for Pediatric Subspecialty Fellows" [Abstract] Eighth Annual Davidoff Education Day, Bronx, NY. May 11, 2011.
46. Esteban-Cruciani N, **Cole PD**, Skae C, Vincencio A, Rajpathak S, Bauman L. "Implementation of a Departmental ACGME Compliant Core Curriculum for Pediatric Subspecialty Fellows" Platform Presentation, Pediatric Academic Societies' & Asian Society for Pediatric Research Joint Meeting, April 30 2011, Denver, Colorado.
47. Li Y, Vijayanathan V, Gulinello M, Cole PD. Intrathecal methotrexate induces focal cognitive deficits and alters CNS folate physiology in rats. *Proceedings of the American Association of Cancer Research. 2010*.
48. Kim S-E, Cole PD, Sohn K-J, et al: Effect of folate and g-glutamyl hydrolase modulation on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. *Proceedings of American Association of Cancer Research, 2010*
49. Kim S-E, Cole PD, Sohn K-J, et al: Effects of foylpolylglutamyl synthase and γ -glutamyl hydrolase modulation on DNA methylation [Abstract]. *Proceedings of American Association of Cancer Research:in press, 2010*
50. Mahadeo K, Wolgast L, McMahan C, Cole PD. Systemic Mastocytosis in a child with t(8;21) Acute Myeloid Leukemia. *Pediatric Blood and Cancer, 2010; 54(6): 828*.
51. Dorfman A, O'Hanlon-Curry J, Cole PD. Methotrexate Induces Measurable Deficits in Verbal Memory Within Days of Exposure. *Pediatric Blood and Cancer, 2010; 54(6): 821*.
52. Kim SE, **Cole PD**, Sohn KJ, Cho RC, Croxford R, Kamen BA, Kim YI. Effect of γ -glutamyl hydrolase modulation on chemosensitivity of colon and breast cancer cells to antifolates and 5-fluorouracil. [Abstract #2862] *Proceedings of the American Association of Cancer Research, 2009*.
53. Dorfman AB, Barros RM, Marion RW, MacAllister WS, **Cole PD**. Chemotherapy induces measurable deficits in cognitive function among children with cancer, within days of exposure. [Abstract # 1678] *Proceedings of the American Association of Cancer Research, 2009*.
54. Li N, Yang R, Thein S, Pressman L, Zheng W, **Cole P**, Gorlick R. Genetically Transforming Human Mesenchymal Stem Cells to Sarcomas: changes in cellular phenotype and expression profile. *Proceedings of the American Association of Cancer Research. 2008*.

55. **Cole PD**, Trippett TM, Drachtman RA, de Alarcon P, Chen L, Schwartz CL. AHOD0321: A COG Phase 2 Study of Weekly Gemcitabine and Vinorelbine for Children with Recurrent or Refractory Hodgkin Disease. [abstract 2318] *Blood* 2007; 110(11):685a.
56. **Cole PD**, Trippett TM, Drachtman RA, de Alarcon P, Chen L, Sposto R, Schwartz CL. AHOD0321: A COG Phase II Study of Weekly Gemcitabine and Vinorelbine in Children with Recurrent or Refractory Hodgkin Disease. [Abstract P082] 7th International Symposium on Hodgkin Lymphoma, Cologne, Germany. November 5, 2007. *Haematologica* 2007; 92 (Suppl. 5): 58.
57. **Cole PD**, Drachtman RA, Smith AK, Masterson M, Glod J, Kamen BA. Phase IIB Trial of Aminopterin in Multiagent Therapy for Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) at High Risk of Relapse. [Abstract 1860] *Blood* 2006; 108 (11): 527a.
58. Litvin-Vechnyak T, Abali EE, **Cole PD**, Bertino JR. Disparate sensitivity of prostate cancer cell lines to antifolates [Abstract 554]. *Proceedings of American Association for Cancer Research*. 2006;47:554.
59. Mishra PJ, Longo GSA, Menon LG, Abali EE, Humeniuk R, **Cole PD**, Kamen BA, Banerjee D and Bertino JR. The 829C→T single nucleotide polymorphism in the 3' UTR of the dihydrofolate reductase gene results in methotrexate resistance and is rare among non-Japanese American patients [Abstract 1274]. *Proceedings of American Association for Cancer Research*, 47: 1274, 2006.
60. **Cole PD**, Smith AK, Velasquez L, Shenkerman A, Kamen BA. "What is New is Really Old! Pharmacodynamic and Pharmacokinetic Studies Supporting the Replacement of Methotrexate by Aminopterin." [Abstract O01-07] *Pteridines* 2005; 16(2): 46.
61. Saydam G, Celikkaya H, **Cole P**, Bertino JR, Ercikan-Abali EA. mTOR inhibition leads to increased sensitivity to methotrexate. [Abstract #3303] *Proc Amer Assoc Cancer Res* 2005;46:3303.
62. **Cole PD**, Drachtman RA, Masterson M, Shenkerman A, Smith AK, Makori B, Kamen BA. Aminopterin Can Replace Methotrexate for Children with Newly Diagnosed Acute Lymphoblastic Leukemia without Excessive Toxicity. [Abstract #1950] *Blood* 2004;104(11): 538a.
63. **Cole PD**, Escalante A, Smith AK, Kamen BA. Pharmacodynamic equivalence of aminopterin and methotrexate in patients with acute lymphoblastic leukemia. (Abstract #2663). *Proc Am Assn Cancer Research*, 2004.
64. **Cole PD**, Smith AK, Kamen BA. Aminopterin (AMT) is not just another methotrexate (MTX): Differences in metabolism may account for increased potency and utility as an anti-folate (Abstract #3572). *Proc Am Assn Cancer Research*; 2003;44: 816a.
65. **Cole PD**, Drachtman R, Smith AK, Larson RA, Winick NJ, Hawkins D, Holcenberg J, Kelly K, Kamen BA. Phase II trial of oral aminopterin for adults and children with refractory acute leukemia (Abstract #3715). *Proc Am Assn Cancer Research*; 2002; 43: 749a.
66. **Cole PD**, Smith AK, Kamen BA. Overcoming methotrexate resistance in osteosarcoma cell lines using nucleoside analogs (Abstract 2068). *Proceedings of the American Society of Clinical Oncology*, 2001; 20: 80b.
67. Drachtman RA, **Cole PD**, James JS, Aisner J, Smith AK, Kamen BA. Methotrexate-induced neurotoxicity is associated with elevated CSF Homocysteine and can be reversed by dextromethorphan, an NMDA-R antagonist. *Proceedings of the American Society of Clinical Oncology*, 2001.
68. **Cole PD**, Gorlick R, Banerjee D, Tong WP, Smith A, Kamen BA, Bertino JR. Effects of Overexpression of γ -glutamyl hydrolase (GGH) on methotrexate metabolism and resistance. [abstract #4980] *Proceedings of the American Association for Cancer Research*, 2000.
69. Li WW, **Cole P**, Martin DS, Banerjee D, Bertino JR. Methylthioadenosine phosphorylase (MTAP) status determines sensitivity to L-alanosine in human soft tissue cell lines and is enhanced by 6-methylmercaptopyrimidine riboside (MMPR). *Proceedings of the American Association for Cancer Research*, 41: 240 2000.
70. **Cole PD**, Kamen BA, Gorlick R, Banerjee D, Bertino JR. Accumulation of methotrexate (MTX) polyglutamates does not correlate with foyllypolyglutamate synthetase (FPGS) or gamma-glutamyl hydrolase (GGH) mRNA as measured by quantitative RT-PCR. [abstract #1137] *Proceedings of the American Society of Hematology*, 1999.
71. **Cole PD**, Gorlick R, Longo G, Deckert PM, Banerjee D, Bertino JR. Development of a quantitative RT-PCR assay for the measurement of Gamma Glutamyl Hydrolase. [abstract #2949] *Proceedings of the American Association for Cancer Research*, 1998; 39:433.

72. Gorlick R, **Cole P**, Longo G, Bertino JR. The role of Gamma-Glutamyl Hydrolase and Folylpolylglutamate synthetase in methotrexate polyglutamylation.[abstract #P57] *Leukemia* 1998; 12: 285.
73. **Cole PD**, Trautman P, Montoya D. Parent-child communication and behavior of deaf children. [abstract] *Proceedings of the American Academy of Child and Adolescent Psychiatry*, 1993.

C. Chapters, Editorials, and Reviews

1. Gennarini L, **Cole PD**. Safety of limited therapeutic monitoring after high-dose methotrexate in developing countries. *Pediatr Blood Cancer*. 2020;e28540. <https://doi.org/10.1002/pbc.28540>
2. **Cole PD**, Kelly KM. Hodgkin Lymphoma, in Rudolph CD et al. (eds): *Rudolph's Pediatrics (23rd Ed)*. McGraw Hill Medical, New York, 2018.
3. **Cole PD**, Figueiredo L, Bertino JR: Folate Antagonists, in Kufe DW, Bast RC, Hait WN, et al (eds): *Cancer Medicine 9 (ed 9th)*. Hamilton, ON, BC Decker, 2017. ISBN: 978-1-118-93469-2.
4. **Cole PD** Does genetic susceptibility increase risk for neurocognitive decline among patients with acute lymphoblastic leukemia? *Future Oncology*. 2015; 11(13): 1855-8; DOI 10.2217/fon.15.117.
5. **Cole PD**, Kamen BA: Folate Antagonists, in Kufe DW, Bast RC, Hait WN, et al (eds): *Cancer Medicine 8 (ed 8th)*. Hamilton, ON, BC Decker, 2010.
6. **Cole PD**. Hematopoietic Growth Factors in Pediatric Patients. *Pediatrics In Review*. 2009; 30(1): 30-31.
7. Mantadakis E, **Cole PD**, Kamen BA. High-dose methotrexate in acute lymphoblastic leukemia: Where is the evidence for its continued use? *Pharmacotherapy* 2005; 25(5): 748-55.
8. **Cole PD**, Zebala JA, Kamen BA. Antimetabolites: a New Perspective. *Drug Discovery Today: Therapeutic Strategies* 2005; 2(4): 337-42.
9. **Cole PD**, Kamen BA: Folate Antagonists, in Kufe DW, Bast RC, Hait WN, et al (eds): *Cancer Medicine 7 (ed 7th)*. Hamilton, ON, BC Decker, 2006
10. **Cole PD**, Kamen BA. "Beriberi" Interesting. *Journal of Pediatric Hematology and Oncology*, 2003; 25(12): 924-6.
11. Kamen BA, **Cole PD**, Bertino JR. Folate Antagonists. In Holland JF and Frei E, Eds. *Cancer Medicine*, 6th Edition. Hamilton: B.C. Decker Inc.; 2003.
12. Kamen BA, **Cole P**. Folate Antagonists. In Bertino JR, Aaronson SA, Borst P, Eds. *Encyclopedia Of Cancer*, 2nd Edition. Academic Press, Inc.; 2002.
13. Kamen BA, **Cole PD**, Bertino JR. Folate Antagonists. In Holland JF and Frei E, Eds. *Cancer Medicine*, 5th Edition. Hamilton: B.C. Decker Inc.; 2000.
14. **Cole PD**, Kamen BA. High-dose methotrexate is lethal to rats. Why give it to children? *Pediatric Hematology and Oncology*, 2000; 17:609-13.

Invited Presentations:

1. "Treating Pediatric Patients with Relapsed or Refractory Hodgkin Lymphoma: A Multiple Choice Exercise" V-SYMPHONY (Virtual Symposium of Pediatric Hematology/Oncology of New York) Lecture Series. October 12, 2020.
2. "Improving Therapy for Children with Acute Lymphoblastic Leukemia" Pediatric Grand Rounds, Children's Hospital of New Jersey, Newark Beth Israel, Newark, NJ. November 13, 2019.
3. "What's all this excitement about immunotherapy for children with cancer?" Pediatric Grand Rounds, Englewood Hospital and Medical Center, Englewood, NJ. November 12, 2019.
4. "Dissecting the pathophysiology of chemotherapy-induced cognitive deficits" Research Seminar, Mouse Imaging Centre, Hospital for Sick Children. Toronto, ON, Canada. April 25, 2019.
5. "Reducing late effects of curative therapy for childhood cancer" Pediatric Grand Rounds, University Hospital, Newark, NJ. March 20, 2019.
6. "Improving Therapy for Children with Acute Lymphoblastic Leukemia" Pediatric Grand Rounds, Robert Wood Johnson University Hospital, Rutgers RWJMS. New Brunswick, NJ. March 7, 2019.

7. "Dissecting the pathophysiology of chemotherapy-induced cognitive deficits: translational studies pointing to therapeutic interventions" Rutgers Cancer Institute, Newark, NJ. November 12, 2018.
8. "Approach to Anemia" Pediatric Resident Rounds. Unterburg Children's Hospital at Monmouth Medical Center. October 31, 2018.
9. "Improving therapy for children with acute lymphoblastic leukemia" Pediatric Grand Rounds. St. Barnabas Hospital. Bronx, NY. October 16, 2018.
10. "The Way Forward: Strategies for Incorporating Checkpoint Inhibitors in Combination Therapy for Pediatric Patients with Hodgkin Lymphoma." Accelerate/European Medicines Agency (EMA) Pediatric Strategy Forum, London, UK. September 5, 2018.
11. "Treatment for Relapsed / Refractory Hodgkin Lymphoma in The Children's Oncology Group: Past Success and Future Directions" Consorcio Latinoamericano de Enfermedades Hematooncológicas Pediátricas; Puerto Alegre, Rio Grande do Sul, Brazil. July 1, 2017.
12. "Pediatric Approach to Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma" Hematology Grand Rounds, Montefiore Medical Center, Bronx, NY. May 19, 2017.
13. "Phase III study of response adapted therapy for the treatment of children with newly diagnosed very high risk Hodgkin Lymphoma" International Symposium on Hodgkin Lymphoma, Cologne, Germany. 23 October 2016.
14. "Incorporating targeted therapies into treatment for adolescents and young adults with Hodgkin lymphoma." Hematology Grand Rounds, Montefiore Medical Center, Bronx, NY. 8 January 2016.
15. "Precision Medicine: Developing a personalized approach to reduce toxicity from therapy for childhood leukemia" Pediatric Hematology/Oncology Special Seminar, University of Alabama at Birmingham, Birmingham AL. 18 December 2015.
16. "Cognitive deficits induced by chemotherapy for childhood leukemia: translational studies pointing to therapeutic interventions." Special Seminar, Child Health Institute of New Jersey. New Brunswick, NJ. 3 December 2015.
17. "Reducing cognitive deficits among survivors of childhood leukemia" Pediatric Grand Rounds, Rutgers / Robert Wood Johnson University Hospital. New Brunswick, NJ. 3 December 2015.
18. "Genetic susceptibility to toxicity of therapy for childhood leukaemia" Glasgow Pediatric Research Symposium. Glasgow, UK. 9 October 2015.
19. "Strategies Incorporating Targeted Therapies for Patients with Hodgkin Lymphoma" Rutgers Cancer Institute of New Jersey, June 24, 2015.
20. "New approaches to antibody based therapies" Roundtable discussion facilitator. Damon Runyon Cancer Research Foundation/Lilly Oncology, Accelerating Cancer Cures Research Symposium, New York, NY, March 3, 2015.
21. "Genetic factors associated with increased risk of cognitive deficits after therapy for childhood leukemia." Pediatric Hematology/Oncology Divisional Seminar, Columbia University Medical Center, January 12, 2015.
22. "Explaining interpatient variation in treatment efficacy and toxicity" Pediatric Rheumatology Grand Rounds, The Children's Hospital at Montefiore. December 16, 2014.
23. "Targeted Therapy for Patients with Hodgkin Lymphoma: Spotlight on Brentuximab vedotin" Congreso Nacional de Oncología, 22nd Annual Meeting of the Sociedad Mexicana de Oncología; Ixtapa, Mexico. October 25, 2014.
24. "Targeted Therapy for Patients with non-Hodgkin Lymphoma" Congreso Nacional de Oncología, 22nd Annual Meeting of the Sociedad Mexicana de Oncología; Ixtapa, Mexico. October 25, 2014.
25. "Challenges Faced by Adolescents and Young Adults with Cancer" Pediatric Grand Rounds, Englewood Hospital and Medical Center. Englewood, NJ. October 14, 2014.
26. "Brentuximab vedotin: Implications of targeted therapy for childhood lymphomas" Congreso Internacional de Oncología y Hematología Pediátrica, La Agrupación Mexicana de Onco-Hematología Pediátrica, Querétaro, Mexico. June 27, 2014.
27. "Relapsed and Refractory Hodgkin Lymphoma: Incorporation of Novel Agents" Childhood, Adolescent, and Young Adult Hodgkin Lymphoma, 2nd International Symposium. Berlin, Germany. May 9, 2014.

28. "Meet the Expert Session – 2nd line treatment, difficult cases", Expert Panel Member. Childhood, Adolescent, and Young Adult Hodgkin Lymphoma, 2nd International Symposium. Berlin, Germany. May 10, 2014.
29. "Drug Therapy for Patients with Hematologic Disorders" and "Reducing Long Term Effects of Treatment for Hematologic Conditions" Hematologic Diseases and Disorders Interdisciplinary Symposium, 1199SEIU Institute for Continuing Education. New York, NY. July 13, 2013.
30. "Preventing Cognitive Dysfunction Among Patients Treated for Leukemia" Hematology Grand Rounds, Montefiore Medical Center. June 7, 2013.
31. "Childhood Cancer Survivorship: The Persistent Costs of Curative Therapy." Pediatric Grand Rounds. Englewood Hospital and Medical Center. Englewood, NJ. February 5, 2013.
32. "Reducing Treatment-Induced Cognitive Dysfunction Among Patients With Cancer." Pediatric Grand Rounds. Staten Island University Hospital, Staten Island, NY. January 17, 2013.
33. "Reducing Treatment-Induced Cognitive Dysfunction Among Patients With Cancer." Department of Pediatrics Grand Rounds. The Children's Hospital at Montefiore, New York, NY. October 10, 2012.
34. "Improving therapy for adolescents and young adults with leukemia" Department of Pediatrics Grand Rounds, Norwalk Hospital, Norwalk, CT. March 27, 2012.
35. "Reducing chemotherapy-induced cognitive dysfunction among cancer survivors" Pediatric Hematology/Oncology Divisional Seminar, Columbia University Medical Center, September 12, 2011.
36. "Strategies to Overcome Intrinsic or Acquired Resistance to Methotrexate" Division of Hematology Grand Rounds, Montefiore Medical Center. February 25, 2011.
37. "What happened to my CBC? Answers from a hematologist" Department of Pediatrics Grand Rounds, Norwalk Hospital. November 30, 2010.
38. "What happened to my CBC? Answers from a hematologist" Department of Pediatrics Grand Rounds, Englewood Hospital and Medical Center. March 23, 2010.
39. "Treatment for Acute Lymphoblastic Leukemia in Adolescents and Young Adults" Department of Medicine/Hematology Grand Rounds, Montefiore Medical Center. February 19, 2010.
40. "Preventing Chemotherapy-Induced Cognitive Dysfunction" St. Jude Children's Research Hospital, Cancer Prevention and Control Grand Rounds. November 9, 2009.
41. "Neurocognitive Dysfunction among Survivors of Childhood Leukemia" Blythedale Children's Hospital, Westchester, NY. October 15, 2009.
42. "Umbilical Cord Stem Cell Banking: A Hematologist's Perspective" Pediatric Grand Rounds, Norwalk Hospital, Norwalk, CT. March 24, 2009.
43. "Detecting and Preventing Treatment-Induced Cognitive Dysfunction Among Children with Cancer" Children's Evaluation and Rehabilitation Center Grand Rounds, Albert Einstein College of Medicine. February 23, 2009.
44. "Presentation and Diagnosis of Common Childhood Cancers" Pediatric Grand Rounds, St. John's Riverside, November 19, 2008.
45. "Successes and Challenges in the Treatment of Childhood ALL" Pediatric Grand Rounds. Stamford Hospital. October 30, 2008.
46. "Introduction to Acute Lymphoblastic Leukemia in Childhood" Department of Radiation Oncology Grand Rounds, Montefiore Medical Center. August 15, 2008.
47. "Don't Panic!! How Common Childhood Signs and Symptoms Can Be Mistaken for Cancer" Pediatric Grand Rounds, Englewood Hospital and Medical Center, June 3, 2008
48. "Chemobrain: Neurotoxic effects of therapy for childhood cancer" Children's Evaluation and Rehabilitation Center Grand Rounds, Albert Einstein College of Medicine. November 19, 2007.
49. "Preventing Treatment-Induced Neurocognitive Dysfunction Among Patients With Cancer" Faculty Research Conference, Montefiore Medical Center. September 24, 2007.

50. "After Chemotherapy: Complications and Cognitive Effects in Children" Clinical Grand Rounds, Children's Specialized Hospital, Mountainside, NJ. December 13, 2006.
51. "Successes and Challenges in the Treatment of Childhood ALL" Bi-Annual Cancer Symposium: Focusing on Lymphoma, Jersey Shore University Medical Center, October 24, 2006.
52. "Ameliorating the Toxicity of Cancer Chemotherapy" Pediatric Grand Rounds, Robert Wood Johnson University Hospital. September 21, 2006.
53. "What is New is Really Old! Pharmacodynamic and Pharmacokinetic Studies Supporting the Replacement of Methotrexate by Aminopterin." Presented at the 13th International Symposium on Chemistry and Biology of Pteridines and Folates, June 21, 2005; Egmond aan Zee, The Netherlands.
54. "General Principles of Cancer Therapy" Mini Med School for High School Students, RWJMS; Piscataway, NJ, April 13, 2005.
55. "What Can the Pathophysiology of Alzheimer's Disease Teach Us About Chemotherapy-Induced Neurotoxicity?" Featured Talk, Eastern Society for Pediatric Research Annual Meeting; Greenwich, CT, March 5, 2005.
56. "Umbilical Cord Blood Stem Cells" Pediatric Grand Rounds, Englewood Hospital and Medical Center, Englewood, NJ, December 21, 2004.
57. "Differences in intracellular metabolism may account for the increased potency and utility of aminopterin relative to methotrexate." Eastern Society for Pediatric Research, Greenwich, CT, March 22, 2003.
58. "Innovative Treatment for Children with Leukemia" Pediatric Grand Rounds, Robert Wood Johnson University Hospital, New Brunswick, NJ, September 20, 2001.
59. "Overcoming methotrexate resistance in osteosarcoma cell lines using nucleoside analogs." Molecular Basis of Antifolate Function Meeting, Dunkeld, Scotland, May, 2001.
60. "Childhood Cancer Update: Successes and Challenges in the Treatment of Leukemia" Lois F. Pollack Symposium on Pediatric Hematology and Oncology, New Brunswick, NJ, October 19, 2001.
61. "Brain Tumors in Childhood" New Jersey Cancer Registrars Meeting, Princeton, NJ, September 21, 2000.